Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Status and phase: Completed; Phase 2; Phase 1

Conditions: Sars-CoV2; Pneumonia, Interstitial; COVID; Pneumonia, Viral; Covid-19; Pneumonia; Coronavirus

Treatments: Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells; Other: Standard treatment according to the Clinical protocols

Study type: Interventional

Funder types: Other

Identifiers

NCT04382547

IBCE_MSC2(Covid)

Details and patient eligibility

About

Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Full description

During the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. The positive outlook for the effectiveness of MSCs is due to the following:

• knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs;
• high tropism of MSCs to lung tissue when administered intravenously;
• the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure;
• positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.

Enrollment: 32 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• PCR-confirmed Covid-19 pneumonia
• respiratory failure

Exclusion criteria

• diagnosed cancer

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

32 participants in 2 patient groups

mesenchymal stem cells

Experimental group

Description:

Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Treatment:

Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Other: Standard treatment according to the Clinical protocols

control

Active Comparator group

Description:

Patients with Covid-19 associated pneumonia receiving standard treatment

Treatment:

Other: Standard treatment according to the Clinical protocols